Product
NGM621
1 clinical trial
1 indication
Indication
Geographic AtrophyClinical trial
A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)Status: Completed, Estimated PCD: 2022-08-16